Endosomal gene expression: A new indicator for prostate cancer patient prognosis?

Oncotarget

Volumn 6, Issue 35, 2015, Pages 37919-37929

  Johnson, Ian R D ^a   Parkinson Lawrence, Emma J ^a   Keegan, Helen ^b,c   Spillane, Cathy D ^c   Barry O'Crowley, Jacqui ^b   Watson, William R ^d   Selemidis, Stavros ^e   Butler, Lisa M ^f   O'Leary, John J ^b,c   Brooks, Doug A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Pathology Research Laboratory   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Biomarkers; Endosomal gene expression; mRNA; Prognosis; Prostate cancer

Indexed keywords

ACID CERAMIDASE; CATHEPSIN B; EARLY ENDOSOME ANTIGEN 1; MESSENGER RNA; MYOSIN I; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SOMATOMEDIN B RECEPTOR; SORTILIN; SYNTAXIN; SYNTAXIN 12; TUMOR MARKER; UNCLASSIFIED DRUG; APPL1 PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; CELL CYCLE PROTEIN; ESCRT PROTEIN; NOX4 PROTEIN, HUMAN; PDCD6IP PROTEIN, HUMAN; RAB PROTEIN; RAB5C PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VESICULAR TRANSPORT ADAPTOR PROTEIN; VESICULAR TRANSPORT PROTEIN;

APPL1 GENE; ARTICLE; BIOGENESIS; BLOOD SAMPLING; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; EEA1 GENE; ENDOSOME; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NOX4 GENE; PDCD6IP GENE; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RAB5A GENE; REAL TIME POLYMERASE CHAIN REACTION; SORT1 GENE; TUMOR GENE; CANCER GRADING; COHORT ANALYSIS; DISEASE COURSE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; BIOMARKERS, TUMOR; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; COHORT STUDIES; DISEASE PROGRESSION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; ENDOSOMES; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; NADPH OXIDASE; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RAB5 GTP-BINDING PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; VESICULAR TRANSPORT PROTEINS;

EID: 84947786217     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6114     Document Type: Article

References (37)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63:11-30.
2. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A and Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European Urology. 2011; 60:106-117.
3. Tarhan F, Orçun A, Küçükercan I, çamursoy N and Kuyumcuoglu U. Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology. 2005; 66:1234-1238.
4. Aaltomaa S, Karja V, Lipponen P, Isotalo T, Kankkunen JP, Talja M and Mokka R. Reduced alpha-and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Research. 2005; 25:4707-4712.
5. Markert EK, Mizuno H, Vazquez A and Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:21276-21281.
6. Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC, Greenberg NM, Butler LM and Tilley WD. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer. 2012; 131:662-672. doi: 610.1002/ijc.26414. Epub 22012 Jan 26424.
7. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D and Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002; 287:1662-1670.
8. Vaarala MH, Hirvikoski P, Kauppila S and Paavonen TK. Identification of androgen-regulated genes in human prostate. Mol Med Report. 2012; 6:466-472.
9. Sartori DA and Chan DW. Biomarkers in prostate cancer: what's new? Current opinion in oncology. 2014; 26:259-264.
10. Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury JS, Sauter G, Brawer M, Stone S, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. The Journal of urology. 2014; 192:409-414.
11. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European urology. 2014.
12. Nguyen HG, Welty CJ and Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Current opinion in urology. 2015; 25:65-70.
13. Johnson IR, Parkinson-Lawrence EJ, Butler LM and Brooks DA. Prostate cell lines as models for biomarker discovery: Performance of current markers and the search for new biomarkers. The Prostate. 2014; 74:547-560.
14. Johnson IR, Parkinson-Lawrence EJ, Shandala T, Weigert R, Butler LM and Brooks DA. Altered endosome biogenesis in prostate cancer has biomarker potential. Molecular cancer research: MCR. 2014; 12:1851-1862.
15. Kallunki T, Olsen OD and Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2012.
16. Nomura T and Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest. 2005; 52:1-9.
17. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB and Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007; 39:41-51.
18. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM and Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. The Journal of clinical investigation. 2004; 113:913-923.
19. de Hoon MJ, Imoto S, Nolan J and Miyano S. Open source clustering software. Bioinformatics. 2004; 20:1453-1454.
20. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
21. AACR A. (2012). Cancer in Australia: an overview 2012. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW.
22. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, et al. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine. 2009; 360:1320-1328.
23. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, DiBlasio CJ, Reuther A, Klein EA and Kattan MW. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:7005-7012.
24. Murphy L, Prencipe M, Gallagher WM and Watson RW. Commercialized biomarkers: new horizons in prostate cancer diagnostics. Expert Rev Mol Diagn. 2015; 15:491-503.
25. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Glover WL, Jr. and Bostwick DG. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. The Journal of urology. 2012; 188:1726-1731.
26. Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, Neves AF, Nasciutti LE, Goulart LR and Gimba ER. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012; 12:507.
27. Ruckhaberle E, Holtrich U, Engels K, Hanker L, Gatje R, Metzler D, Karn T, Kaufmann M and Rody A. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric. 2009; 12:502-513.
28. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI and Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer. 2000; 29:137-146.
29. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 2001; 20:173-193.
30. Kela I, Harmelin A, Waks T, Orr-Urtreger A, Domany E and Eshhar Z. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate. 2009; 69:1034-1044.
31. Liong ML, Lim CR, Yang H, Chao S, Bong CW, Leong WS, Das PK, Loh CS, Lau BE, Yu CG, Ooi EJ, Nam RK, Allen PD, Steele GS, Wassmann K, Richie JP, et al. Blood-based biomarkers of aggressive prostate cancer. PLoS ONE. 2012; 7:e45802.
32. March-Villalba JA, Martinez-Jabaloyas JM, Herrero MJ, Santamaria J, Alino SF and Dasi F. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS ONE. 2012; 7:e43470.
33. Pelosi G, Schianchi E, Dell'orto P, Veronesi G, Spaggiari L, Pasini F, Sozzi G, Brambilla E, Griso C and Viale G. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch. 2006; 448:7-15.
34. Rasiah KK, Stricker PD, Haynes AM, Delprado W, Turner JJ, Golovsky D, Brenner PC, Kooner R, O'Neill GF, Grygiel JJ, Sutherland RL and Henshall SM. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer. 2003; 98:2560-2565.
35. Peshavariya H, Dusting GJ, Jiang F, Halmos LR, Sobey CG, Drummond GR and Selemidis S. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch Pharmacol. 2009; 380:193-204.
36. Vickers AJ, Roobol MJ and Lilja H. Screening for prostate cancer: early detection or overdetection? Annu Rev Med. 2012; 63:161-170.
37. Aizer AA, Chen MH, Hattangadi J and D'Amico AV. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int. 2013.